Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab ... moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic ...

Atopic dermatitis, the most common form of eczema, can lead to dry, itchy, and inflamed skin. It often comes and goes in flares. Atopic dermatitis affects people of all skin tones, but it doesn't ...

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis ... like Sanofi and Regeneron’s Dupixent (dupilumab), which dominates ...

such as atopic dermatitis and asthma – providing patients with one treatment that might help multiple atopy conditions. We look forward to bringing Dupixent to the more than 300,000 CSU patients ...

Lebrikizumab improves anxiety and depression symptoms in adolescents with moderate-to-severe atopic dermatitis, with significant PROMIS score improvements after 52 weeks. The therapy enhances ...

But major changes can also be majorly stressful, which can put many people with atopic dermatitis, a type of eczema, at risk for a flare. Maybe your new dorm room is a haven for dust mites or you ...

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Raelle Kennedy is a patient advocate in the atopic dermatitis space. She uses her personal story and media background to spread awareness about managing inflammatory conditions. Atopic dermatitis ...

With this FDA decision, Dupixent is now approved for seven chronic, debilitating atopic conditions driven in part by underlying type 2 inflammation, several of which have been shown to co-morbidly ...

Dupixent was first approved in 2017 as a treatment for atopic dermatitis. It’s Sanofi’s top-selling product, accounting for more than €13 billion (about $14.7 billion) in revenue in 2024.

It’s common for Black people with atopic dermatitis to feel especially self-conscious and embarrassed about their skin, says Caroline Opene, MD, a dermatologist at UCLA Health in Santa Monica, ...